Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: U.S. Dermal Fillers Market

4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. U.S. Dermal Fillers Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Regulatory Scenario in the U.S.
5.3. Licensing Agreement Analysis
5.4. COVID-19 Impact Analysis

6. U.S. Dermal Fillers Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Biodegradable
6.3.2. Non-biodegradable
6.4. Market Attractiveness Analysis, by Product

7. U.S. Dermal Fillers Market Analysis and Forecast, by Material
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Material, 2017–2031
7.3.1. Calcium Hydroxylapatite
7.3.2. Hyaluronic Acid
7.3.3. Collagen
7.3.4. Poly-L-Lactic Acid
7.3.5. Polymethylmethacrylate (PMMA)
7.3.6. Fat
7.3.7. Others
7.4. Market Attractiveness Analysis, by Material

8. U.S. Dermal Fillers Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Facial Line Correction Treatment
8.3.2. Lip Enhancement
8.3.3. Scar Treatment
8.3.4. Others
8.4. Market Attractiveness Analysis, by Application

9. U.S. Dermal Fillers Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Dermatology Clinics
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user

10. Competition Landscape
10.1. Market Player - Competition Matrix (by tier and size of companies)
10.2. Market Share Analysis, by Company, 2020
10.3. Company Profiles
10.3.1. AbbVie
10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.1.2. Product Portfolio
10.3.1.3. SWOT Analysis
10.3.1.4. Strategic Overview
10.3.2. Advanced Aesthetic Technologies, Inc.
10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.2.2. Product Portfolio
10.3.2.3. SWOT Analysis
10.3.2.4. Strategic Overview
10.3.3. Anika Therapeutics, Inc.
10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.3.2. Product Portfolio
10.3.3.3. SWOT Analysis
10.3.3.4. Strategic Overview
10.3.4. BioPlus Co., Ltd.
10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.4.2. Product Portfolio
10.3.4.3. SWOT Analysis
10.3.4.4. Strategic Overview
10.3.5. Croma-Pharma GmbH
10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.5.2. Product Portfolio
10.3.5.3. SWOT Analysis
10.3.5.4. Strategic Overview
10.3.6. Cytophil, Inc.
10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.6.2. Product Portfolio
10.3.6.3. SWOT Analysis
10.3.6.4. Strategic Overview
10.3.7. DR. Korman Laboratories.
10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.7.2. Product Portfolio
10.3.7.3. SWOT Analysis
10.3.7.4. Strategic Overview
10.3.8. Galderma
10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.8.2. Product Portfolio
10.3.8.3. SWOT Analysis
10.3.8.4. Strategic Overview
10.3.9. Huons USA
10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.9.2. Product Portfolio
10.3.9.3. SWOT Analysis
10.3.9.4. Strategic Overview
10.3.10. Merz Pharma GmbH & Co. KGaA
10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.10.2. Product Portfolio
10.3.10.3. SWOT Analysis
10.3.10.4. Strategic Overview
10.3.11. Revance
10.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.11.2. Product Portfolio
10.3.11.3. SWOT Analysis
10.3.11.4. Strategic Overview
10.3.12. Sinclair Pharma
10.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.12.2. Product Portfolio
10.3.12.3. SWOT Analysis
10.3.12.4. Strategic Overview
10.3.13. Suneva Medical, Inc.
10.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.13.2. Product Portfolio
10.3.13.3. SWOT Analysis
10.3.13.4. Strategic Overview
10.3.14. Syneron Medical Ltd.
10.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.14.2. Product Portfolio
10.3.14.3. SWOT Analysis
10.3.14.4. Strategic Overview
10.3.15. TEOXANE Laboratories
10.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.15.2. Product Portfolio
10.3.15.3. SWOT Analysis
10.3.15.4. Strategic Overview



List of Figures

List of Figures
Figure 01: U.S. Dermal Filler Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: U.S. Dermal Filler Market Value Share, by Product, 2020
Figure 03: U.S. Dermal Filler Market Value Share, Material, 2020
Figure 04: U.S. Dermal Filler Market Value Share, by Application, 2020
Figure 05: U.S. Dermal Filler Market Value Share, End-user, 2020
Figure 06: U.S. Dermal Filler Market Attractiveness Analysis, by Product, 2021–2031
Figure 07: U.S. Dermal Filler Market Revenue (US$ Mn), by Biodegradable, 2017–2031
Figure 08: U.S. Dermal Filler Market Revenue (US$ Mn), by Non-biodegradable, 2017–2031
Figure 09: U.S. Dermal Filler Market Attractiveness Analysis, by Product, 2021–2031
Figure 10: U.S. Dermal Filler Market Attractiveness Analysis, by Material, 2021–2031
Figure 11: U.S. Dermal Filler Market Revenue (US$ Mn), by Calcium Hydroxylapatite, 2017–2031
Figure 12: U.S. Dermal Filler Market Revenue (US$ Mn), by Hyaluronic Acid, 2017–2031
Figure 13: U.S. Dermal Filler Market Revenue (US$ Mn), by Collagen, 2017–2031
Figure 14: U.S. Dermal Filler Market Revenue (US$ Mn), by Poly-L-lactic Acid, 2017–2031
Figure 15: U.S. Dermal Filler Market Revenue (US$ Mn), by PMMA, 2017–2031
Figure 16: U.S. Dermal Filler Market Revenue (US$ Mn), by Fat, 2017–2031
Figure 17: U.S. Dermal Filler Market Revenue (US$ Mn), by Others, 2017–2031
Figure 18: U.S. Dermal Filler Market Attractiveness Analysis, by Material, 2021–2031
Figure 19: U.S. Dermal Filler Market Attractiveness Analysis, by Application, 2021–2031
Figure 20: U.S. Dermal Filler Market Attractiveness Analysis, by Application, 2021–2031
Figure 21: U.S. Dermal Filler Market Revenue (US$ Mn), by Facial Line Correction Treatment, 2017–2031
Figure 22: U.S. Dermal Filler Market Revenue (US$ Mn), by Lip Enhancement, 2017–2031
Figure 23: U.S. Dermal Filler Market Revenue (US$ Mn), by Scar Treatment, 2017–2031
Figure 24: U.S. Dermal Filler Market Revenue (US$ Mn), by Others, 2017–2031
Figure 25: U.S. Dermal Filler Market Attractiveness Analysis, by End-user, 2021–2031
Figure 26: U.S. Dermal Filler Market Attractiveness Analysis, by End-user, 2021–2031
Figure 27: U.S. Dermal Filler Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 28: U.S. Dermal Filler Market Revenue (US$ Mn), by Dermatology Clinics, 2017–2031
Figure 29: U.S. Dermal Filler Market Revenue (US$ Mn), by Aesthetic Centers, 2017–2031
Figure 30: U.S. Dermal Filler Market Revenue (US$ Mn), by Others, 2017–2031

List of Tables

List of Tables
Table 01: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 02: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by Material, 2017–2031
Table 03: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 04: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031